Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.
The Sussex, England-based biotechnology company said the trial is currently evaluating its novel virus-like particle-based peanut allergy vaccine candidate, VLP Peanut.
In part A of the trial, patients with peanut had undergone skin-prick testing, Allergy Therapeutics said.
It was then determined that no safety signals had been observed. Consequently, it was safe to proceed with incremental subcutaneous dosing in healthy subjects in the phase 1 stage, and in peanut allergic patients in the phase 2a part of the trial.
Chief Executive Officer Manuel Llobet said: ‘This is a key milestone in our journey to offer transformative outcomes to patients living with peanut allergies. We are excited to begin gathering data supportive of efficacy using biomarker technology which is aligned with recent [US Food & Drug Administration] workshop thinking on demonstrating efficacy in clinical trials.
‘We look forward to the complete results of this trial and continue to work towards the required planning for the phase II.’
Shares in Allergy Therapeutics were up 0.8% at 2.62 pence each in London on Tuesday afternoon.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
